Literature DB >> 23884058

Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction.

Martin Schaefer1, Rahul Sarkar, Crisanto Diez-Quevedo.   

Abstract

Psychiatric comorbidity is a common problem in patients with substance use disorders. Patients with psychiatric diseases and/or substance abuse have an increased risk for hepatitis C virus (HCV) infection. Furthermore, psychiatric problems occur frequently during antiviral treatment and may be associated with the use of interferon alpha (IFN-α) but also with the primary psychiatric condition. As a consequence, substance abuse and/or acute psychiatric problems are still important reasons for nontreatment of chronic HCV infection. However, prospective and controlled data from recent years showed that if an interdisciplinary treatment is provided, patients with substance use disorders and/or psychiatric diseases do not differ regarding sustained virologic response or IFN-α-associated complications such as depression when compared with controls. Moreover, depression as the most important acute IFN-α-associated psychiatric adverse event can be acutely treated or even prevented by antidepressant pretreatment. Other, more rare but severe complications such as mania, psychotic symptoms, or delirium need individual psychiatric interventions.

Entities:  

Keywords:  depression; hepatitis C; interferon; management; psychiatric adverse events; ribavirin

Mesh:

Year:  2013        PMID: 23884058     DOI: 10.1093/cid/cit266

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

Review 1.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA.

Authors:  Kaitlin Grosgebauer; Tyler S Bartholomew; Katherine Huynh; Travis Cos
Journal:  J Prim Prev       Date:  2021-03-18

3.  Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Authors:  Maryam Alavi; Tim Spelman; Gail V Matthews; Paul S Haber; Carolyn Day; Ingrid van Beek; Nick Walsh; Barbara Yeung; Julie Bruneau; Kathy Petoumenos; Kate Dolan; John M Kaldor; Gregory J Dore; Margaret Hellard; Jason Grebely
Journal:  Int J Drug Policy       Date:  2015-05-21

4.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

5.  A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C.

Authors:  Marilyn Huckans; Bret Fuller; Viva Wheaton; Sarah Jaehnert; Carilyn Ellis; Michael Kolessar; Daniel Kriz; Jeanne Renee Anderson; Kristin Berggren; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Jennifer M Loftis
Journal:  J Psychosom Res       Date:  2014-08-07       Impact factor: 3.006

6.  New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups.

Authors:  Marta Miarons; Azhara Sánchez-Ulayar; Glòria Sempere; Sergio Marín; Josep Maria Castellví
Journal:  Eur J Hosp Pharm       Date:  2018-01-27

7.  Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Authors:  Stevan A Gonzalez; Daniel S Fierer; Andrew H Talal
Journal:  Addict Disord Their Treat       Date:  2017-05-17

8.  Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).

Authors:  Tangui Barré; Fabienne Marcellin; Vincent Di Beo; Jessica Delorme; Teresa Rojas Rojas; Philippe Mathurin; Camelia Protopopescu; François Bailly; Marion Coste; Nicolas Authier; Maria Patrizia Carrieri; Benjamin Rolland
Journal:  Addiction       Date:  2019-11-20       Impact factor: 6.526

9.  Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.

Authors:  Andrés Marco; José J Antón; Joan Trujols; Pablo Saíz de la Hoya; José de Juan; Inmaculada Faraco; Joan A Caylà
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

10.  Hepatitis C virus prevention and care for drug injectors: the French approach.

Authors:  Jean-Michel Delile; Victor de Ledinghen; Marie Jauffret-Roustide; Perrine Roux; Brigitte Reiller; Juliette Foucher; Daniel Dhumeaux
Journal:  Hepatol Med Policy       Date:  2018-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.